Clinical characteristics and immunotherapy response in paraneoplastic neurologic syndrome patients with increased number of high-risk antibodies
ObjectiveTo investigate the differences of clinical characteristics and treatment outcomes between paraneoplastic neurologic syndrome (PNS) patients with one high-risk antibody and patients with two high-risk antibodies.MethodsWe retrospectively analyzed the data of 51 PNS patients with high-risk an...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1520493/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553930762321920 |
|---|---|
| author | Gong Wang Mao Chen Fei Gao Meng Guo Maohua Li Qian He Jiaojin Jiang Cheng Huang Xiaoyan Chen Rui Xu |
| author_facet | Gong Wang Mao Chen Fei Gao Meng Guo Maohua Li Qian He Jiaojin Jiang Cheng Huang Xiaoyan Chen Rui Xu |
| author_sort | Gong Wang |
| collection | DOAJ |
| description | ObjectiveTo investigate the differences of clinical characteristics and treatment outcomes between paraneoplastic neurologic syndrome (PNS) patients with one high-risk antibody and patients with two high-risk antibodies.MethodsWe retrospectively analyzed the data of 51 PNS patients with high-risk antibody. Clinical data were extracted from the patients’ electronic medical records. Clinical presentations, cerebrospinal fluid (CSF) parameters, radiological characteristics and treatment outcomes between patients with one high-risk antibody and patients with two high-risk antibodies were analyzed.Results41 patients with 1 high-risk antibody and 10 patients with 2 high-risk antibodies were enrolled in this study. It was found that psychobehavioral abnormality (OR = 11.327, 95% CI: 1.371 to 93.602, P = 0.024), bowel and bladder dysfunction (OR = 23.537, 95% CI: 1.753 to 316.005, P = 0.017), and total protein of CSF (OR = 61.556, 95% CI: 2.926 to 1294.974, P = 0.008) were risk factors for increased number of high-risk antibodies in PNS. After immunotherapy treatment, Expanded Disability Status Scale (EDSS) scores in PNS patients with 2 high-risk antibodies were higher than that in PNS patients with 1 high-risk antibody (4.8 ± 2.4 vs. 3.0 ± 2.4, p = 0.043). EDSS change analysis also revealed that average EDSS score decreased after treatment in PNS with 1 Ab group while increased in PNS with 2 Abs group (p = 0.032).ConclusionsPsychobehavioral abnormality, bowel and bladder dysfunction, and total protein of CSF were three variables associated with increased number of high-risk antibodies in PNS patients, while increased number of high-risk antibodies might indicate a poor immunotherapy response. Our findings might help to understand the association of PNS patients’ clinical features and high-risk antibodies, as well as to guide clinical practice. |
| format | Article |
| id | doaj-art-ee157c22dce9406fae039b5c9b9777d1 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-ee157c22dce9406fae039b5c9b9777d12025-01-09T06:10:18ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.15204931520493Clinical characteristics and immunotherapy response in paraneoplastic neurologic syndrome patients with increased number of high-risk antibodiesGong WangMao ChenFei GaoMeng GuoMaohua LiQian HeJiaojin JiangCheng HuangXiaoyan ChenRui XuObjectiveTo investigate the differences of clinical characteristics and treatment outcomes between paraneoplastic neurologic syndrome (PNS) patients with one high-risk antibody and patients with two high-risk antibodies.MethodsWe retrospectively analyzed the data of 51 PNS patients with high-risk antibody. Clinical data were extracted from the patients’ electronic medical records. Clinical presentations, cerebrospinal fluid (CSF) parameters, radiological characteristics and treatment outcomes between patients with one high-risk antibody and patients with two high-risk antibodies were analyzed.Results41 patients with 1 high-risk antibody and 10 patients with 2 high-risk antibodies were enrolled in this study. It was found that psychobehavioral abnormality (OR = 11.327, 95% CI: 1.371 to 93.602, P = 0.024), bowel and bladder dysfunction (OR = 23.537, 95% CI: 1.753 to 316.005, P = 0.017), and total protein of CSF (OR = 61.556, 95% CI: 2.926 to 1294.974, P = 0.008) were risk factors for increased number of high-risk antibodies in PNS. After immunotherapy treatment, Expanded Disability Status Scale (EDSS) scores in PNS patients with 2 high-risk antibodies were higher than that in PNS patients with 1 high-risk antibody (4.8 ± 2.4 vs. 3.0 ± 2.4, p = 0.043). EDSS change analysis also revealed that average EDSS score decreased after treatment in PNS with 1 Ab group while increased in PNS with 2 Abs group (p = 0.032).ConclusionsPsychobehavioral abnormality, bowel and bladder dysfunction, and total protein of CSF were three variables associated with increased number of high-risk antibodies in PNS patients, while increased number of high-risk antibodies might indicate a poor immunotherapy response. Our findings might help to understand the association of PNS patients’ clinical features and high-risk antibodies, as well as to guide clinical practice.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1520493/fullPNShigh-risk antibodynumber of antibodiesrisk factorsimmunotherapy response |
| spellingShingle | Gong Wang Mao Chen Fei Gao Meng Guo Maohua Li Qian He Jiaojin Jiang Cheng Huang Xiaoyan Chen Rui Xu Clinical characteristics and immunotherapy response in paraneoplastic neurologic syndrome patients with increased number of high-risk antibodies Frontiers in Immunology PNS high-risk antibody number of antibodies risk factors immunotherapy response |
| title | Clinical characteristics and immunotherapy response in paraneoplastic neurologic syndrome patients with increased number of high-risk antibodies |
| title_full | Clinical characteristics and immunotherapy response in paraneoplastic neurologic syndrome patients with increased number of high-risk antibodies |
| title_fullStr | Clinical characteristics and immunotherapy response in paraneoplastic neurologic syndrome patients with increased number of high-risk antibodies |
| title_full_unstemmed | Clinical characteristics and immunotherapy response in paraneoplastic neurologic syndrome patients with increased number of high-risk antibodies |
| title_short | Clinical characteristics and immunotherapy response in paraneoplastic neurologic syndrome patients with increased number of high-risk antibodies |
| title_sort | clinical characteristics and immunotherapy response in paraneoplastic neurologic syndrome patients with increased number of high risk antibodies |
| topic | PNS high-risk antibody number of antibodies risk factors immunotherapy response |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1520493/full |
| work_keys_str_mv | AT gongwang clinicalcharacteristicsandimmunotherapyresponseinparaneoplasticneurologicsyndromepatientswithincreasednumberofhighriskantibodies AT maochen clinicalcharacteristicsandimmunotherapyresponseinparaneoplasticneurologicsyndromepatientswithincreasednumberofhighriskantibodies AT feigao clinicalcharacteristicsandimmunotherapyresponseinparaneoplasticneurologicsyndromepatientswithincreasednumberofhighriskantibodies AT mengguo clinicalcharacteristicsandimmunotherapyresponseinparaneoplasticneurologicsyndromepatientswithincreasednumberofhighriskantibodies AT maohuali clinicalcharacteristicsandimmunotherapyresponseinparaneoplasticneurologicsyndromepatientswithincreasednumberofhighriskantibodies AT qianhe clinicalcharacteristicsandimmunotherapyresponseinparaneoplasticneurologicsyndromepatientswithincreasednumberofhighriskantibodies AT jiaojinjiang clinicalcharacteristicsandimmunotherapyresponseinparaneoplasticneurologicsyndromepatientswithincreasednumberofhighriskantibodies AT chenghuang clinicalcharacteristicsandimmunotherapyresponseinparaneoplasticneurologicsyndromepatientswithincreasednumberofhighriskantibodies AT xiaoyanchen clinicalcharacteristicsandimmunotherapyresponseinparaneoplasticneurologicsyndromepatientswithincreasednumberofhighriskantibodies AT ruixu clinicalcharacteristicsandimmunotherapyresponseinparaneoplasticneurologicsyndromepatientswithincreasednumberofhighriskantibodies |